Anti-Sema3A antibodies and their uses for treating eye or ocular diseases

Anti-Sema3A antibodies target Sema3A to inhibit its vasorepressive effect, promoting retinal revascularization and reducing pathological neovascularization, addressing the inefficiencies of current treatments for ischemic retinopathies.

AU2020267874B2Pending Publication Date: 2026-07-09BOEHRINGER INGELHEIM INT GMBH
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
AU · AU
Patent Type
Applications
Current Assignee / Owner
BOEHRINGER INGELHEIM INT GMBH
Filing Date
2020-05-08
Publication Date
2026-07-09

AI Technical Summary

Technical Problem

Current treatments for ischemic retinopathies, such as diabetic retinopathy, fail to address the underlying ischemia that drives pathological neovascularization, leading to inefficient vision preservation and high rates of visual loss.

Method used

Development of anti-Sema3A antibodies that specifically bind to Sema3A, inhibiting its vasorepressive effect and promoting retinal revascularization, thereby treating or preventing conditions like diabetic retinopathy, diabetic macular edema, and retinal neovascularization.

Benefits of technology

The anti-Sema3A antibodies effectively inhibit Sema3A-induced cytoskeletal collapse in retinal endothelial cells, promoting vascular regeneration and reducing pathological neovascularization, thus improving revascularization and reducing retinal permeability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000080_0000
    Figure 00000080_0000
  • Figure 00000081_0000
    Figure 00000081_0000
  • Figure 00000081_0001
    Figure 00000081_0001
Patent Text Reader

Abstract

The present invention relates to antibodies and fragments thereof that target semaphorin 3A (Sema3A). More specifically, anti-Sema3A antibodies and methods of use for the treatment of various diseases or disorders are disclosed.
Need to check novelty before this filing date? Find Prior Art